Skip to content

Coronary Hemodynamic Analysis Stimulating Index of Microcirculatory Resistance promotes the diagnosis and treatment of micro-vascular dysfunction

Coronary Hemodynamic Analysis Stimulating Index of Microcirculatory Resistance promotes the diagnosis and treatment of micro-vascular dysfunction

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000035616
Enrollment
Unknown
Registered
2020-08-15
Start date
2021-01-01
Completion date
Unknown
Last updated
2020-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Interventions

acute myocardial infarction:Nil
slow flow:Nil
stable CAD:Nil

Sponsors

Zhongshan Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-85 years old, hospitalized in the Department of Cardiology of our hospital, willing to undergo coronary angiography; 2. Coronary angiography showed slow blood flow in 20 patients; 3. Emergency interventional therapy in 20 patients with acute myocardial infarction; 4. Elective interventional therapy in 20 patients with stable coronary heart disease; 5. With independent civil capacity, agreed to participate in the clinical study and follow-up, and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients are allergic to contrast agent and other related drugs; 2. Patients with bleeding tendency, active gastrointestinal ulcer history, cerebral hemorrhage or arachnoid hemorrhage history, stroke history within half a year, antiplatelet agents and anticoagulant treatment contraindications can not be anticoagulant therapy; 3. Other diseases may affect the life expectancy of less than 12 months; 4. Pregnant or lactating; 5. Severe liver and kidney dysfunction (ALT > 5 times ULN, eGFR 200 mmol/L); 6. Active bleeding; 7. Bleeding disorders or malignant tumor diseases; 8. Patients with contraindications to the use of antithrombotic drugs; 9. Patients who are not suitable for this study in the opinion of the investigator.

Design outcomes

Primary

MeasureTime frame
all-cause death;Non-fatal re-infarction;

Countries

China

Contacts

Public ContactChen Zhangwei

Zhongshan Hospital, Fudan University

chen.zhangwei@zs-hospital.sh.cn+86 13918612111

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026